Search Results Search Sort by RelevanceMost Recent State of the Art and Science Nov 2004 Chronic Myeloid Leukemia and the Application of Rational Drug Design Richard Maury Stone, MD Imatinib is a pharmaceutical therapy recently approved by the FDA to help treat chronic myeloid leukemia. Virtual Mentor. 2004;6(11):497-500. doi: 10.1001/virtualmentor.2004.6.11.cprl1-0411. Health Law Nov 2004 Wright v. Fred Hutchinson Cancer Center: Maintaining Patient and Public Trust in Clinical Research Laura Lin, MBA and Bryan A. Liang, MD, PhD, JD An ethical case explores a lawsuit against Fred Hutchinson Cancer Center of Seattle by patients who claimed they were not told of the full risks associated with a clinical trial they participated in. Virtual Mentor. 2004;6(11):501-504. doi: 10.1001/virtualmentor.2004.6.11.hlaw1-0411. Medicine and Society Nov 2004 Gatekeeping and the FDA's Role in Human Subjects Protection Daniel Carpenter, PhD The FDA bears the responsibility to monitor clinical trials and protect human subjects from harm. Virtual Mentor. 2004;6(11):512-514. doi: 10.1001/virtualmentor.2004.6.11.msoc1-0411. Policy Forum Nov 2004 Genetic Samples and Genetic Philanthropy Michael E. Berens, PhD and Gary E. Marchant, PhD, JD Genetic research is threatened by lack of samples, and public policy should be developed to encourage public participation. Virtual Mentor. 2004;6(11):509-511. doi: 10.1001/virtualmentor.2004.6.11.pfor2-0411. In the Literature Nov 2004 Determining Research through Underdetermined Treatment Abraham P. Schwab, PhD Paul Miller and Charles Weijer defend the concept of equipoise in medical research in a recent journal article. Virtual Mentor. 2004;6(11):488-489. doi: 10.1001/virtualmentor.2004.6.11.jdsc1-0411. State of the Art and Science Dec 2004 The Impact of Recent Clinical Trials on National Cholesterol Education Program Adult Treatment Panel III Guidelines Niharika P. Bansal Recent clinical trials have led to updates in the management of patients with high cholesterol. Virtual Mentor. 2004;6(12):550-553. doi: 10.1001/virtualmentor.2004.6.12.cprl1-0412. Medicine and Society Jul 2024 How Should Harm Reduction Be Included in Care Continua for Patients With Opioid Use Disorder? Elizabeth Salisbury-Afshar, MD, MPH, Catherine J. Livingston, MD, MPH, and Ricky N. Bluthenthal, PhD Equity requires full access to evidence-based OUD care, housing stability, and education and employment opportunities. AMA J Ethics. 2024;26(7):E562-571. doi: 10.1001/amajethics.2024.562. Policy Forum Jul 2024 How Should the Use of Opioids Be Regulated to Motivate Better Clinical Practice? Ellen L. Edens, MD, MPE, MA, Gabriela Garcia Vassallo, MD, and Robert Heimer, PhD Reconsider regulatory and clinical frameworks for prescribing long-term opioid therapy for pain and prescribing opioids to treat OUD. AMA J Ethics. 2024;26(7):E551-561. doi: 10.1001/amajethics.2024.551. History of Medicine Jul 2024 Drawing on Black and Queer Communities’ Harm Reduction Histories to Improve Overdose Prevention Strategies and Policies Sterling Johnson, JD, MA and Kimberly L. Sue, MD, PhD Black and queer community-based harm reduction practices can help guide development and implementation of anti-overdose interventions. AMA J Ethics. 2024;26(7):E580-586. doi: 10.1001/amajethics.2024.580. Case and Commentary Jul 2024 When Are “Paraphernalia” Critical Medical Supplies? Adriane M. dela Cruz, MD, PhD, Donald Egan, MD, MPH, Sarah E. Baker, MD, MA, and John Z. Sadler, MD Evidence of harm reduction interventions’ morbidity and mortality benefits is abundant and of high quality. AMA J Ethics. 2024;26(7):E527-533. doi: 10.1001/amajethics.2024.527. Pagination First page « First Previous page ‹ Previous … Page 18 Page 19 Page 20 Page 21 Page 22 Page 23 Current page 24 Page 25 Page 26 Next page Next › Last page Last »
State of the Art and Science Nov 2004 Chronic Myeloid Leukemia and the Application of Rational Drug Design Richard Maury Stone, MD Imatinib is a pharmaceutical therapy recently approved by the FDA to help treat chronic myeloid leukemia. Virtual Mentor. 2004;6(11):497-500. doi: 10.1001/virtualmentor.2004.6.11.cprl1-0411.
Health Law Nov 2004 Wright v. Fred Hutchinson Cancer Center: Maintaining Patient and Public Trust in Clinical Research Laura Lin, MBA and Bryan A. Liang, MD, PhD, JD An ethical case explores a lawsuit against Fred Hutchinson Cancer Center of Seattle by patients who claimed they were not told of the full risks associated with a clinical trial they participated in. Virtual Mentor. 2004;6(11):501-504. doi: 10.1001/virtualmentor.2004.6.11.hlaw1-0411.
Medicine and Society Nov 2004 Gatekeeping and the FDA's Role in Human Subjects Protection Daniel Carpenter, PhD The FDA bears the responsibility to monitor clinical trials and protect human subjects from harm. Virtual Mentor. 2004;6(11):512-514. doi: 10.1001/virtualmentor.2004.6.11.msoc1-0411.
Policy Forum Nov 2004 Genetic Samples and Genetic Philanthropy Michael E. Berens, PhD and Gary E. Marchant, PhD, JD Genetic research is threatened by lack of samples, and public policy should be developed to encourage public participation. Virtual Mentor. 2004;6(11):509-511. doi: 10.1001/virtualmentor.2004.6.11.pfor2-0411.
In the Literature Nov 2004 Determining Research through Underdetermined Treatment Abraham P. Schwab, PhD Paul Miller and Charles Weijer defend the concept of equipoise in medical research in a recent journal article. Virtual Mentor. 2004;6(11):488-489. doi: 10.1001/virtualmentor.2004.6.11.jdsc1-0411.
State of the Art and Science Dec 2004 The Impact of Recent Clinical Trials on National Cholesterol Education Program Adult Treatment Panel III Guidelines Niharika P. Bansal Recent clinical trials have led to updates in the management of patients with high cholesterol. Virtual Mentor. 2004;6(12):550-553. doi: 10.1001/virtualmentor.2004.6.12.cprl1-0412.
Medicine and Society Jul 2024 How Should Harm Reduction Be Included in Care Continua for Patients With Opioid Use Disorder? Elizabeth Salisbury-Afshar, MD, MPH, Catherine J. Livingston, MD, MPH, and Ricky N. Bluthenthal, PhD Equity requires full access to evidence-based OUD care, housing stability, and education and employment opportunities. AMA J Ethics. 2024;26(7):E562-571. doi: 10.1001/amajethics.2024.562.
Policy Forum Jul 2024 How Should the Use of Opioids Be Regulated to Motivate Better Clinical Practice? Ellen L. Edens, MD, MPE, MA, Gabriela Garcia Vassallo, MD, and Robert Heimer, PhD Reconsider regulatory and clinical frameworks for prescribing long-term opioid therapy for pain and prescribing opioids to treat OUD. AMA J Ethics. 2024;26(7):E551-561. doi: 10.1001/amajethics.2024.551.
History of Medicine Jul 2024 Drawing on Black and Queer Communities’ Harm Reduction Histories to Improve Overdose Prevention Strategies and Policies Sterling Johnson, JD, MA and Kimberly L. Sue, MD, PhD Black and queer community-based harm reduction practices can help guide development and implementation of anti-overdose interventions. AMA J Ethics. 2024;26(7):E580-586. doi: 10.1001/amajethics.2024.580.
Case and Commentary Jul 2024 When Are “Paraphernalia” Critical Medical Supplies? Adriane M. dela Cruz, MD, PhD, Donald Egan, MD, MPH, Sarah E. Baker, MD, MA, and John Z. Sadler, MD Evidence of harm reduction interventions’ morbidity and mortality benefits is abundant and of high quality. AMA J Ethics. 2024;26(7):E527-533. doi: 10.1001/amajethics.2024.527.